Royalty Pharma
RPRX
RPRX
231 hedge funds and large institutions have $9.59B invested in Royalty Pharma in 2021 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 92 increasing their positions, 78 reducing their positions, and 38 closing their positions.
Holders
231
Holders Change
-4
Holders Change %
-1.7%
% of All Funds
4.06%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
36
Increased
92
Reduced
78
Closed
38
Calls
$45.5M
Puts
$17.1M
Net Calls
+$28.4M
Net Calls Change
+$41.8M
Top Buyers
| 1 |
1
Berkshire Hathaway
Omaha,
Nebraska
|
$475M |
| 2 |
2
Morgan Stanley
New York
|
$2.07B |
| 3 |
3
Vanguard Group
Malvern,
Pennsylvania
|
$1.09B |
| 4 |
4
BlackRock
New York
|
$559M |
| 5 |
5
Geode Capital Management
Boston,
Massachusetts
|
$151M |
